Abstract
Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer Jochen H LorchDana Farber Cancer institute, Boston, MA, USAAbstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments. Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
